Oxford BioMedica’s cancer vaccine was a victim of Sanofi-aventis’ portfolio review after the French pharma company handed back rights to Trovax® ten months after it failed in a late stage clinical trial. On the upside, demonstrating its confidence in the UK-based biotech, Sanofi pledged an additional £34 M (US$50 M) for gene-based treatments for eye disease.